Literature DB >> 2560294

Restricted replication of human adenovirus type 5 in mouse cell lines.

G E Blair1, S C Dixon, S A Griffiths, M E Zajdel.   

Abstract

Infection of mouse BALB/c 3T3 cells by adenovirus 5 resulted in at least 1000-fold lowered yields of virus compared to human cells. The molecular basis of this restriction was analysed at the level of viral gene expression. Steady-state levels of viral DNA and RNA were greatly reduced in infected mouse, compared to human cells. Both early region 1A (E1A) and E1B mRNAs were decreased in mouse cells and their protein products were barely detectable by metabolic labelling of infected cells. The E2A-72 kDa protein and the hexon protein were detected by metabolic labelling, and immunocytochemical analysis showed that they were correctly located in nuclei of infected mouse cells. Only a minor proportion of infected mouse 3T3 cells expressed the E2A-72 kDa or hexon proteins. Low yields of virus were obtained by infection of SV40 transformed BALB/c 3T3 cells showing that SV40 does not provide a helper function for adenovirus 5 growth in this cell system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2560294     DOI: 10.1016/0168-1702(89)90026-9

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  32 in total

1.  An activity associated with human chromosome 21 permits nuclear colocalization of the adenovirus E1B-55K and E4orf6 proteins and promotes viral late gene expression.

Authors:  Amy M Chastain-Moore; Terry Roberts; Deborah A Trott; Robert F Newbold; David A Ornelles
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.

Authors:  Christian Jogler; Dennis Hoffmann; Dirk Theegarten; Thomas Grunwald; Klaus Uberla; Oliver Wildner
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Authors:  Mikko Siurala; Riikka Havunen; Dipongkor Saha; Dave Lumen; Anu J Airaksinen; Siri Tähtinen; Víctor Cervera-Carrascon; Simona Bramante; Suvi Parviainen; Markus Vähä-Koskela; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2016-06-30       Impact factor: 11.454

4.  Novel model of innate immunity in corneal infection.

Authors:  Jaya Rajaiya; Xiaohong Zhou; Irina Barequet; Michael S Gilmore; James Chodosh
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-05-15       Impact factor: 2.416

5.  Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo.

Authors:  Anna-Mary Young; Kyra M Archibald; Laura A Tookman; Alexander Pool; Kate Dudek; Carolyn Jones; Sarah L Williams; Katrina J Pirlo; Anne E Willis; Michelle Lockley; Iain A McNeish
Journal:  Mol Ther       Date:  2012-06-26       Impact factor: 11.454

6.  Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.

Authors:  Hong Jiang; Dong Ho Shin; Teresa T Nguyen; Juan Fueyo; Xuejun Fan; Verlene Henry; Caroline C Carrillo; Yanhua Yi; Marta M Alonso; Tiara L Collier; Ying Yuan; Frederick F Lang; Candelaria Gomez-Manzano
Journal:  Clin Cancer Res       Date:  2019-08-27       Impact factor: 12.531

7.  Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus.

Authors:  J M Torres; C Alonso; A Ortega; S Mittal; F Graham; L Enjuanes
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears.

Authors:  J W Moorhead; G H Clayton; R L Smith; J Schaack
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.

Authors:  Yusuke Mochizuki; Hiroshi Tazawa; Koji Demiya; Miho Kure; Hiroya Kondo; Tadashi Komatsubara; Kazuhisa Sugiu; Joe Hasei; Aki Yoshida; Toshiyuki Kunisada; Yasuo Urata; Shunsuke Kagawa; Toshifumi Ozaki; Toshiyoshi Fujiwara
Journal:  Cancer Immunol Immunother       Date:  2020-11-05       Impact factor: 6.968

10.  Adenovirus targets transcriptional and posttranslational mechanisms to limit gap junction function.

Authors:  Patrick J Calhoun; Allen V Phan; Jordan D Taylor; Carissa C James; Rachel L Padget; Michael J Zeitz; James W Smyth
Journal:  FASEB J       Date:  2020-06-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.